A Study of Bitopertin (RO4917838) in Combination With Selective Serotonin Reuptake Inhibitors in Patients With Obsessive-Compulsive Disorder
What is the purpose of this trial?
This multi-center, randomized, double-blind, parallel-group, placebo-controlled study will evaluate the efficacy and safety of bitopertin (RO4917838) in combination with selective serotonin reuptake inhibitors (SSRI) in patients with obsessive-compulsive disorder. Patients will be randomized to receive either bitopertin 30 mg or bitopertin 10 mg or placebo orally daily in addition to their background therapy with an SSRI. Anticipated time on study treatment is 16 weeks.
- 18 Years - 65 Years
- Hoffman-La Roche
- Last Updated:
- Study HIC#: